|
Supplemental Data |
|
Supporting Notes.
Available as:
- HTML Document
- PDF
|
|
Supporting Table 2: Clinical and pathological information associated
with the 112 prostate samples used for DNA microarray analysis.
Available both as:
- MS
Excel spreadsheet
- PDF
|
|
|
Supporting Figure 4: Effect of varying preclustering data filtering
and sample selection criteria.
Available both as:
- HTML Document
- PDF
|
|
|
Supporting Figure 5: Effect of varying preclustering data filtering
and sample selection criteria.
Available both as:
- HTML Document
- PDF
|
|
Supporting Table 3: PAM-derived tumor subclass predictor cross-validation
error rates.
Available as:
- MS Excel spreadsheet
- PDF
|
|
Supporting Table 4: Distribution of grade and stage across gene expression
tumor subgroups.
Available as:
- MS Excel spreadsheet
- PDF
|
|
Supporting Table 5: Differences in expression of genes associated
with high grade/advanced stage/early recurrence between subtype I and subtype
II/III cases.
Available as:
- MS Excel spreadsheet
- PDF
|
|
|
Supporting Figure 6: Effect of varying preclustering data filtering
and sample selection criteria.
Available both as:
- HTML Document
- PDF
|
|
Supporting Table 6: Relationship between tumor grade/stage/preoperative
serum prostate-specific antigen (PSA) and MUC1/AZGP1 immunostaining.
Available as:
- MS Excel spreadsheet
- PDF
|
|